-0.04%
7.30%
13.69%
12.30%
4.65%
-7.51%
35.77%
AI Spotlight on SHL
Company Description
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies.The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems.
The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products.The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy.The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions.
It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services.The company is headquartered in Erlangen, Germany.Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Market Data
| Last Price | 54.96 |
| Change Percentage | -0.04% |
| Open | 54.96 |
| Previous Close | 54.98 |
| Market Cap ( Millions) | 61515 |
| Volume | 468932 |
| Year High | 58.14 |
| Year Low | 47.31 |
| M A 50 | 52.28 |
| M A 200 | 52.04 |
Financial Ratios
| FCF Yield | 2.99% |
| Dividend Yield | 1.73% |
| ROE | 10.66% |
| Debt / Equity | 89.20% |
| Net Debt / EBIDTA | 325.88% |
| Price To Book | 3.38 |
| Price Earnings Ratio | 31.7 |
| Price To FCF | 33.43 |
| Price To sales | 2.75 |
| EV / EBITDA | 18.05 |
News
- Jan -30 - Is Siemens Healthineers AG (ETR:SHL) Trading At A 44% Discount?
- Nov -13 - Siemens Healthineers (XTRA:SHL) Reports Strong Earnings Growth, Acquires Novartis Imaging Business
- Nov -11 - Siemens Healthineers Full Year 2024 Earnings: EPS Misses Expectations
- Nov -10 - Here's What Analysts Are Forecasting For Siemens Healthineers AG (ETR:SHL) After Its Yearly Results
- Nov -06 - Siemens Healthineers Net Profit, Revenue Miss Views
- Oct -15 - For Patients at Risk, a Simple Blood Test Can Help Doctors Predict Likelihood of Future Heart Attack, Other Cardiac Events, and Death
- Sep -15 - Declining Stock and Solid Fundamentals: Is The Market Wrong About Siemens Healthineers AG (ETR:SHL)?
- Aug -19 - Siemens Healthineers Third Quarter 2024 Earnings: Misses Expectations
- Jul -31 - Health Care Roundup: Market Talk
- Jul -31 - Siemens Healthineers Net Profit Rises as Order Momentum Continues
- Jul -30 - New Survey Reveals Burnout in Clinical Labs Impacts Patient Care, Staff Safety; Optimism that Automation, AI Will Help Tackle Challenges
- Jul -30 - The Companies Realizing Theranos’s Failed Dream
- Jul -24 - Human-Centered Engineering in the Lab Can Close the Distance Between Providers and Care: Siemens Healthineers to Exhibit How at ADLM 2024
- May -29 - Is There An Opportunity With Siemens Healthineers AG's (ETR:SHL) 42% Undervaluation?
- May -16 - Siemens to Sell Innomotics to KPS Capital Partners for $3.8 Billion
- May -10 - Stocks to watch this week: Burberry, Vodafone, BT and Walmart
- May -05 - Siemens Healthineers AG (ETR:SHL) stock most popular amongst public companies who own 76%, while individual investors hold 13%
- Apr -26 - Stocks to watch this week: Amazon, Apple, Anglo American and Novo Nordisk
- Apr -14 - Interested In Siemens Healthineers' (ETR:SHL) Upcoming €0.95 Dividend? You Have Four Days Left
- Apr -11 - Infineon Technologies' (ETR:IFX) five-year earnings growth trails the 10% YoY shareholder returns
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Imaging
Expected Growth : 5 %
What the company do ?
Why we expect these perspectives ?
Siemens Healthineers' 5% growth in Imaging is driven by increasing demand for diagnostic imaging, advancements in AI-powered imaging technologies, and growing adoption of digital healthcare platforms. Additionally, the company's strategic partnerships, expanding product portfolio, and geographic expansion into emerging markets contribute to its growth momentum.
Segment n°2 -> Diagnostics
Expected Growth : 5 %
What the company do ?
Why we expect these perspectives ?
Siemens Healthineers' diagnostics segment growth is driven by increasing demand for precision medicine, adoption of digital healthcare, and rising healthcare expenditure. The company's innovative product portfolio, including AI-powered diagnostic tools, and strategic partnerships also contribute to growth. Additionally, the COVID-19 pandemic has accelerated the need for rapid and accurate diagnostic testing, further boosting demand.
Segment n°3 -> Varian
Expected Growth : 7 %
What the company do ?
Why we expect these perspectives ?
Varian's 7% growth driven by increasing demand for cancer treatment, expansion in emerging markets, and strategic partnerships. Additionally, investments in AI-powered radiation oncology solutions, and growing adoption of stereotactic body radiation therapy (SBRT) are contributing to growth. Furthermore, Varian's strong brand reputation, and continuous innovation in proton therapy and multi-room configurations also support its growth momentum.
Segment n°4 -> Advanced Therapies
Expected Growth : 8 %
What the company do ?
Why we expect these perspectives ?
Advanced Therapies from Siemens Healthineers AG is driven by increasing demand for precision medicine, growing adoption of digital healthcare, and rising investments in research and development. Additionally, the segment benefits from Siemens' strong brand reputation, strategic partnerships, and expanding presence in emerging markets, contributing to its 8% growth rate.
Segment n°5 -> Reconciliation
Expected Growth : 4 %
What the company do ?
Why we expect these perspectives ?
Siemens Healthineers AG's 4% growth is driven by increasing demand for diagnostic imaging and laboratory diagnostics, expansion in emerging markets, and strategic acquisitions. Additionally, the company's focus on digitalization, artificial intelligence, and data analytics is enhancing its product offerings, leading to market share gains and revenue growth.
Siemens Healthineers Ag Products
| Product Range | What is it ? |
|---|---|
| Magnetic Resonance Imaging (MRI) Systems | Siemens Healthineers' MRI systems provide high-quality images for accurate diagnosis and treatment of various medical conditions. |
| Computed Tomography (CT) Scanners | Siemens Healthineers' CT scanners offer high-speed, low-dose imaging for precise diagnosis and treatment planning. |
| X-ray Systems | Siemens Healthineers' X-ray systems provide high-quality digital imaging for accurate diagnosis and treatment of various medical conditions. |
| Ultrasound Systems | Siemens Healthineers' ultrasound systems offer high-resolution imaging for accurate diagnosis and treatment of various medical conditions. |
| Molecular Imaging | Siemens Healthineers' molecular imaging solutions provide precise visualization of biological processes for accurate diagnosis and treatment. |
| Laboratory Diagnostics | Siemens Healthineers' laboratory diagnostics solutions provide accurate and efficient testing for various medical conditions. |
| Point of Care Testing | Siemens Healthineers' point of care testing solutions provide rapid and accurate testing at the bedside or in the clinic. |
| Enterprise Imaging | Siemens Healthineers' enterprise imaging solutions provide a unified platform for image management and analysis. |
| Artificial Intelligence (AI) and Analytics | Siemens Healthineers' AI and analytics solutions provide insights and automation for improved clinical decision-making and operational efficiency. |
| Digital Health | Siemens Healthineers' digital health solutions provide a range of digital tools and services for healthcare providers and patients. |
Siemens Healthineers AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Siemens Healthineers AG is low due to the company's strong brand recognition and customer loyalty in the healthcare industry.
Bargaining Power Of Customers
The bargaining power of customers for Siemens Healthineers AG is medium due to the presence of large hospital chains and healthcare providers, but the company's diversified product portfolio and strong relationships with customers mitigate this power.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Siemens Healthineers AG is low due to the company's large scale and diversified supply chain, which reduces dependence on individual suppliers.
Threat Of New Entrants
The threat of new entrants for Siemens Healthineers AG is low due to the high barriers to entry in the healthcare industry, including regulatory hurdles and the need for significant investments in research and development.
Intensity Of Rivalry
The intensity of rivalry for Siemens Healthineers AG is high due to the presence of established competitors such as GE Healthcare and Philips Healthcare, and the need for continuous innovation and investment in research and development to stay competitive.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.38% |
| Debt Cost | 7.60% |
| Equity Weight | 96.62% |
| Equity Cost | 7.60% |
| WACC | 7.60% |
| Leverage | 3.50% |
Siemens Healthineers AG : Quality Control
Siemens Healthineers AG passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHIA.AS | Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The … |
| AZN.L | AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, … |
| SYK | Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use … |
| DRW3.DE | Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, … |
| STE | STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AstraZeneca
A-Score
1-Year Total Return ->
🥈
Drägerwerk
A-Score
1-Year Total Return ->
🥉
Stryker
A-Score
1-Year Total Return ->
4
Philips
A-Score
1-Year Total Return ->
5
Siemens Healthineers
A-Score
1-Year Total Return ->
6
